THY1 and cancer: Remarkably, after in vivo growth, HepG2-slug xenografts maintained CSCs phenotype with the presence of subpopulations of cancer cells harbouring a CD133+ or CD90+ phenotype (Fig. 4B and C) that was not seen in the HepG2 xenografts where the predominant phenotype was CD133− or CD90−.